Medical Technology Leaders to Discuss Open Data During World Patient Safety, Science & Technology Summit
The medical technology field spans a multi-billion dollar market, and corporate competitiveness has long been viewed as the key to staying ahead. But Joe Kiani, Chairman, and CEO of the medical technology company, Masimo, is bringing fierce competitors together for the sake of patient safety.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221005514/en/
Joe Kiani, Founder and Chairman of the Patient Safety Movement Foundation, discusses the importance of open data and interoperability of medical devices. (Photo: Business Wire)
As a strong advocate for patient safety, Kiani founded the Patient Safety Movement Foundation to stem the needless deaths that occur in hospitals every day through preventable medical error. The goal is zero preventable deaths by 2020.
One of the ways to reach such an aggressive goal, says Kiani, is a concept called “interoperability” and he wants to use open data to create a “Patient Data Super Highway” to get to there.
“First of all, it’s the right thing to do,” Kiani says. “People are dying because of the lack of data sharing –algorithms that can warn clinicians and help them with decision making can’t be used because data from medical devices and electronic medical records have historically been walled by the manufacturers.”
Since the first Patient Safety Science & Technology Summit in January 2013, Kiani has convened hundreds of leading clinicians, hospital CEOs, medical technology CEOs, government stakeholders and patient advocates from around the globe to discuss what steps need to be made to get closer to the Foundation’s goal to eliminate preventable deaths in hospitals.
The first challenge is how to get competing MedTech companies like Philips, Medtronic, Masimo and GE to work together on interoperability? The solution is through Open Data Pledges to amass data collected by various medical devices. Data sharing is the key along with protections for patient privacy, but the prize remains patient safety. The information is there, ready for any company or entrepreneur to figure out a way to take “interoperability and with it predictive algorithms and decision support” from concept to reality.
What began with nine companies opting to sign Open Data Pledge in 2013 has now grown to nearly 100 companies, including giants GE, IBM Watson, Medtronic and Philips, who have signed the pledge. And this year, Medtronic CEO Omar Ishrak will lead the panel on Healthcare Technology at the 6th Annual World Patient Safety, Science & Technology Summit in London. It’s a clear sign that more companies are beginning to see the need for interoperability to eliminate preventable deaths in hospitals.
“That’s what makes this year’s World Patient Safety, Science and Technology Summit so exciting,” says Kiani. “We are going to be able to bring together industry leaders, innovators and even rivals to the table in pursuit of patient safety.”
“Zero preventable deaths in a hospital setting by 2020 is a goal worth cooperating for,” Kiani says. “The summit brings together the expertise, technology and the ability to come up with actionable plans and implementation that can save lives.”
The 6th Annual World Patient Healthcare Technology Leadership panelists are:
- Moderator Omar Ishrak , Chairman and CEO, Medtronic – Past President and CEO of General Electric Healthcare Systems, a 12 billion dollar division of GE. He is co-chair of the World Economic Forum’s Health and Healthcare Community and serves on the Board of Directors for Intel, the global technology company.
- Matt Darling , Co-founder, SmartWard – Mr. Darling’s diverse background includes bringing hardware and software solutions in Cybersecurity, Safety-Critical Systems, and Defense.
- Frans van Houten , CEO, Royal Philips – Mr. van Houten also serves as Chairman of the Board of Management and Executive Committees. His expertise in innovation and business transformation has led to improved results at Philips through targeted divestment and the acquisition of complementary health technology businesses. These include U.S. based image-guided therapy leader Volcano and analytics leader Wellcentive.
- Anders Wold , President and CEO, GE Healthcare Clinical Care Solutions - Mr. Wold joined GE with the acquisition of Diasonics/Vingmed Ultrasound, a Norway-based technology start-up. He has 32- years of experience in the ultrasound industry, including product management, sales and marketing while based in Singapore, Paris and Norway. He led the Global Ultrasound business from 2009 to July 2016, growing it into the global industry leader.
- Dr. Charles Murphy , Chief Patient Safety Officer, Inova Heart and Vascular Institute - Dr. Murphy continues to be active in direct patient care as a critical care physician and medical director of the Cardiovascular ICU at Inova. He previously served as Associate Chief Patient Safety Officer for the Duke Health System.
For more information, please visit the Patient Safety Movement Foundation website. Members of the media may request a press pass by visiting http://bit.ly/2mCeyay or by contacting Tanya Lyon – phone (949) 351-2858 or email email@example.com.
About Patient Safety Movement Foundation:
More than 200,000 U.S. patients and three million worldwide die each year from preventable causes. The Patient Safety Movement Foundation (PSMF) was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare to reduce that number of preventable deaths to zero by 2020 (0X2020). Improving patient safety requires a collaborative effort from all stakeholders, including patients, healthcare providers, medical technology companies, government, employers, and private payers. The PSMF works with all stakeholders to address problems with actionable solutions. The Foundation also convenes the World Patient Safety, Science and Technology Summit bringing together some of the world’s best minds for thought-provoking discussions and new ideas that challenge the status quo. By presenting specific, high-impact solutions to meet patient safety challenges, called Actionable Patient Safety Solutions, encouraging medical technology companies to share the data their products are purchased for, and asking hospitals to make commitments to implement Actionable Patient Safety Solutions, the Patient Safety Movement Foundation is working toward zero preventable deaths by 2020. Visit http://patientsafetymovement.org/.
Patient Safety Movement Foundation
Tanya Lyon, 949-351-2858
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine23.3.2018 21:28 | Tiedote
Seoul Semiconductor, a global innovator of LED products and technology, announced on March 23rd that its SunLike Series natural spectrum LED product won the Gold Award at the Elektronik Product of the Year 2018 Awards, hosted by Elektronik (http://www.elektroniknet.de), a leading German electronics publication. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005646/en/ Product of the Year Award from Elektronik Magazine (SunLike) (Photo: Business Wire) As a publication specializing in electrical and electronic components, “Elektronik” is a prestigious magazine with an illustrious history and the largest number of subscribers in Germany. Over the past 20 years, they have conducted annual surveys among their subscribers to find the “most creative and innovative products.” Based on these survey results, Elektronik selects the top product that with the most impact in its corresponding field, and confers the awards accordingl
Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 19:05 | Tiedote
Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the
Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 15:52 | Tiedote
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal
CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 15:50 | Tiedote
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation
Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 15:46 | Tiedote
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c
Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 15:00 | Tiedote
Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at www.aitheon.com/news) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005269/en/ Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme